Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory (R/R) Central Nervous System Lymphoma or Treatment-Naive (TN) Central Nervous System Lymphoma, Results from the Phase Ib Combination Part of HZ-a-018-102 Study

被引：0
|
作者：
Li, Wenbin [1 ]
Kang, Zhuang [1 ]
Chen, Feng [1 ]
Li, Shenglan [1 ]
Chen, Xi [2 ]
Yuan, Xianggui
Yang, Haiyan [4 ]
Qian, Wenbin [3 ]
Hu, Miao [5 ]
Zhang, Yanping [5 ]
Zhou, Xinglu [5 ]
机构：
[1] Capital Med Univ, Beijing Tiantan Hosp, Canc Ctr, Dept Neurooncol, Beijing, Peoples R China
[2] Zhejiang Canc Hosp, Dept Lymphoma, Hangzhou, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Dept Hematol, Hangzhou, Peoples R China
[4] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Lymphoma, Hangzhou, Peoples R China
[5] HealZen Therapeut Co Ltd, Hangzhou, Peoples R China
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-201166
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6482 / 6483
页数：2
相关论文
共 13 条
  • [1] A Phase I/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BTK Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory Central Nervous System Lymphoma
    Li, Wenbin
    Kang, Zhuang
    Chen, Feng
    Li, Shenglan
    Yuan, Xianggui
    Chen, Xi
    Qian, Wenbin
    Yang, Haiyan
    Hu, Miao
    Zhou, Xinglu
    BLOOD, 2023, 142
  • [2] Phase Ib Trial with Dose Expansion of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab and Lenalidomide in Patients with Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
    Grommes, Christian
    Piotrowski, Anna
    Pentsova, Elena
    Nolan, Craig
    Francis, Jasmine
    DeAngelis, Lisa
    Schaff, Lauren
    Mellinghoff, Ingo K.
    BLOOD, 2020, 136
  • [3] Efficacy Analysis of Bruton's Tyrosine Kinase Inhibitor Combined Regimen in the Treatment of Elderly Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma
    Shi, Wenyu
    Ben, Yu
    Zhang, Yaping
    Li, Jianyong
    BLOOD, 2022, 140 : 12121 - 12121
  • [4] Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Combination with Ibrutinib in Relapsed/Refractory Primary Central Nervous System Lymphoma Patients with Prior Exposure to BTK Inhibitor
    Nowakowski, Grzegorz S.
    Dabrowska-Iwanicka, Anna Paulina
    Grommes, Christian
    Tun, Han W.
    D'Angelo, Christopher
    Burguera, Adolfo De la Fuente
    Levi, Etai
    Ramchandren, Radhakrishnan
    Ferreri, Andres Jose Maria
    Choudhary, Gaurav S.
    Zhao, Wanying
    Ferrari, Dora
    Fowle, Meaghan
    Lane, Maureen
    Wang, Catherine
    Taszner, Michal
    BLOOD, 2024, 144 : 6020 - 6021
  • [5] Phase Ib/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab and Lenalidomide in Refractory/Recurrent Primary (PCNSL) and Secondary Central Nervous System Lymphoma (SCNSL)
    Grommes, Christian
    Piotrowski, Anna
    Pentsova, Elena
    Gavrilovic, Igor
    Stone, Jacqueline B.
    Lin, Andrew
    Wongchai, Venissala
    Madzsar, Juli T.
    Malani, Rachna
    Nolan, Craig
    Francis, Jasmine
    DeAngelis, Lisa
    Schaff, Lauren
    Mellinghoff, Ingo K.
    BLOOD, 2022, 140 : 3807 - 3808
  • [6] Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma
    Narita, Yoshitaka
    Nagane, Motoo
    Mishima, Kazuhiko
    Terui, Yasuhito
    Arakawa, Yoshiki
    Yonezawa, Hajime
    Asai, Katsunori
    Fukuhara, Noriko
    Sugiyama, Kazuhiko
    Shinojima, Naoki
    Kitagawa, Junsaku
    Aoi, Arata
    Nishikawa, Ryo
    NEURO-ONCOLOGY, 2021, 23 (01) : 122 - 133
  • [7] THE BRUTON'S TYROSINE KINASE INHIBITOR IBRUTINIB IS HIGHLY ACTIVE AND TOLERABLE IN RELAPSED OR REFRACTORY (R/R) AND TREATMENT NAIVE (TN) CLL PATIENTS, UPDATED RESULTS OF A PHASE IB/II STUDY
    O'Brien, S.
    Furman, R.
    Coutre, S.
    Burger, J.
    Blum, K.
    Sharman, J.
    Flinn, I.
    Grant, B.
    Heerema, N.
    Johnson, A.
    Navarro, T.
    James, D.
    Hedrick, E.
    Byrd, J.
    HAEMATOLOGICA, 2012, 97 : 218 - 218
  • [8] Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
    Nagane, Motoo
    Narita, Yoshitaka
    Mishima, Kazuhiko
    Terui, Yasuhito
    Arakawa, Yoshiki
    Yonezawa, Hajime
    Asai, Katsunori
    Fukuhara, Noriko
    Sugiyama, Kazuhiko
    Shinojima, Naoki
    Kitagawa, Junsaku
    Aoi, Arata
    Nishikawa, Ryo
    BLOOD, 2019, 134
  • [9] Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients
    Marion, Alcantara
    Marion, Chevrier
    Fabrice, Jardin
    Anna, Schmitt
    Caroline, Houillier
    Lucie, Oberic
    Olivier, Chinot
    Franck, Morschhauser
    Frederic, Peyrade
    Roch, Houot
    Khe, Hoang-Xuan
    Herve, Ghesquieres
    Carole, Soussain
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [10] Safety and Efficacy of Intrathecal Liposome-Encapsulated Cytarabine for Central Nervous System (CNS) Prophylaxis in Adult Patients with Burkitt and Atypical Burkitt Lymphoma Treated with the R-CODOX-M/R-IVAC (Magrath) Regimen: Results of a Phase H Study.
    Frigeri, Ferdinando
    Russo, Filippo
    Arcamone, Manuela
    Fraira, Chiara
    Russo, Gennaro
    Capobianco, Gaetana
    Becchimanzi, Cristina
    Cuomo, Arturo
    Marcacci, Gianpaolo
    Esposito, Gennaro
    De Filippi, Rosaria
    Corazzelli, Gaetano
    Vitolo, Umberto
    Pinto, Antonio
    BLOOD, 2009, 114 (22) : 1431 - 1431
12